Summaries for patients. Treatment outcomes for patients with multidrug-resistant tuberculosis.

نویسنده

  • Sonal S Munsiff
چکیده

V. Leimane. What is the problem and what is known about it so far? Tuberculosis is a bacterial infection that usually involves the lungs, although it can also involve other parts of the body. When a person inhales tuberculosis bacteria, an initial infection develops that does not cause disease. The bacteria can lie dormant in the body after this initial infection but cause disease years later, when the body is under stress, because of poor nutrition or disease. A person with active tuberculosis disease is contagious, meaning that the infection can spread from one person to another, almost always through coughing. Once a person is diagnosed with tuberculosis, treatment involves taking a combination of drugs, usually by mouth, for at least 6 months. Unfortunately, some forms of tuberculosis are not sensitive to the 2 usual drugs used to treat it (multidrug-resistant tuberculosis). Multidrug-resistant tuberculosis requires treatment with more and/or different drugs. When treating tuberculosis, doctors test the fluid patients cough up (sputum smear) to see whether it contains bacteria. A negative sputum smear means that the patient is no longer infectious. Usually these samples are also sent for culture growth, which often takes 8 to 10 weeks for a result. It is important to know when the tuberculosis bacteria no longer grow in culture because negative cultures mean that the disease is improving.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

The Incidence of Amikacin Ototoxicity in Multidrug-Resistant Tuberculosis Patients

Amikacin has been shown to irreversibly suppressCochlear activity.The aim of this study is to assess the incidence of amikacinototoxicity in multidrug-resistant tuberculosis patients and riskfactors associated withthis ototoxicity.In this cross-sectional study, 41 patientswith multidrug-resistant tuberculosis (MDR-TB) were included.All patients received fixed dose of intravenous amikacin(500 mg...

متن کامل

The Incidence of Amikacin Ototoxicity in Multidrug-Resistant Tuberculosis Patients

Amikacin has been shown to irreversibly suppressCochlear activity.The aim of this study is to assess the incidence of amikacinototoxicity in multidrug-resistant tuberculosis patients and riskfactors associated withthis ototoxicity.In this cross-sectional study, 41 patientswith multidrug-resistant tuberculosis (MDR-TB) were included.All patients received fixed dose of intravenous amikacin(500 mg...

متن کامل

Study of HIV seroprevalence in Pulmonary Tuberculosis Patients with Special Reference to Multidrug Resistant Mycobacteria

This study was planned to determine HIV seroprevalence among pulmonary tuberculosis patients, to characterize the isolated mycobacteria into typical and atypical strains and to evaluate the drug resistant pattern of mycobacterial isolates. The study aims to correlate multidrug resistance (MDR) and HIV seropositivity status in pulmonary tuberculosis patients. During the year 1994-1997, 750 pulmo...

متن کامل

Audiological Evaluation of Patients Taking Kanamycin for Multidrug Resistant Tuberculosis

Introduction: The incidence of multidrug resistant tuberculosis is increasing in developing countries. Aminoglycosides are an integral part of second-line drugs, however ototoxicity is a major limitation for their use. This study aims to determine the extent of hearing loss in patients taking one of the commonly prescribed drugs for Multidrug resistant tuberculosis (MDR-TB), Kanamycin, at a Gov...

متن کامل

Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis

Multidrug-resistant and extensively drug-resistant tuberculosis (TB) are associated with worse treatment outcomes for patients, including higher mortality, than for drug-sensitive tuberculosis. Delamanid (OPC-67683) is a novel anti-TB medication with demonstrated activity against multidrug-resistant disease. Patients who participated in the previously reported randomised, placebo-controlled tri...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Annals of internal medicine

دوره 144 9  شماره 

صفحات  -

تاریخ انتشار 2006